Molecular Templates Stock Price, News & Analysis (NASDAQ:MTEM)

$8.86 -0.37 (-4.01 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$8.86
Today's Range$8.83 - $9.30
52-Week Range$3.85 - $13.25
Volume53,034 shs
Average Volume96,764 shs
Market Capitalization$228.74 million
P/E Ratio-5.24
Dividend YieldN/A
Beta3.07

About Molecular Templates (NASDAQ:MTEM)

Molecular Templates logoMolecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:MTEM
CUSIP88580720
Phone+1-512-8961555

Debt

Debt-to-Equity Ratio0.02%
Current Ratio6.16%
Quick Ratio6.16%

Price-To-Earnings

Trailing P/E Ratio-5.24260355029586
Forward P/E Ratio-6.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$76.92 million
Price / Sales3.10
Cash FlowN/A
Price / CashN/A
Book Value$3.06 per share
Price / Book2.90

Profitability

Trailing EPS($1.69)
Net Income$-24,090,000.00
Net MarginsN/A
Return on Equity-56.65%
Return on Assets-47.31%

Miscellaneous

Employees15
Outstanding Shares26,900,000

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates shares reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) announced its quarterly earnings results on Monday, July, 31st. The biotechnology company reported $0.22 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.77) by $0.99. The biotechnology company earned $3 million during the quarter. View Molecular Templates' Earnings History.

When will Molecular Templates make its next earnings announcement?

Molecular Templates is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Molecular Templates.

Where is Molecular Templates' stock going? Where will Molecular Templates' stock price be in 2018?

2 Wall Street analysts have issued twelve-month price targets for Molecular Templates' shares. Their forecasts range from $0.40 to $10.00. On average, they expect Molecular Templates' stock price to reach $5.20 in the next twelve months. View Analyst Ratings for Molecular Templates.

Who are some of Molecular Templates' key competitors?

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the folowing people:

  • Harold E. Selick Ph.D., Chairman of the Board (Age 62)
  • Eric E. Poma Ph.D., Chief Executive Officer, Chief Scientific Officer, Director
  • Adam D. Cutler, Chief Financial Officer (Age 43)
  • Conrad Jordaan, Senior Vice President - Finance, Corporate Controller
  • Nenad Sarapa, Senior Vice President - Clinical Development
  • Joel A. Fernandes, Vice President - Finance, Controller (Age 45)
  • Mark Hopkins J.D. Ph.D., Vice President - Intellectual Property and Assistant General Counsel
  • Kristen Quigley, Vice President - Clinical Operations (Age 45)
  • Barbara A. Ruskin Ph.D. J.D., General Counsel and Chief Patent Officer
  • Tillman E Pearce M.D., Chief Medical Officer (Age 59)

Who owns Molecular Templates stock?

Molecular Templates' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.27%), Lyon Street Capital LLC (0.21%), Alps Advisors Inc. (0.11%), BlueCrest Capital Management Ltd (0.06%), Two Sigma Investments LP (0.05%) and Paloma Partners Management Co (0.04%). View Institutional Ownership Trends for Molecular Templates.

Who bought Molecular Templates stock? Who is buying Molecular Templates stock?

Molecular Templates' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Lyon Street Capital LLC, Alps Advisors Inc., BlueCrest Capital Management Ltd, Two Sigma Investments LP, Paloma Partners Management Co and Wells Fargo & Company MN. View Insider Buying and Selling for Molecular Templates.

How do I buy Molecular Templates stock?

Shares of Molecular Templates can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Molecular Templates' stock price today?

One share of Molecular Templates stock can currently be purchased for approximately $8.86.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $228.74 million and generates $76.92 million in revenue each year. The biotechnology company earns $-24,090,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Molecular Templates employs 15 workers across the globe.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 Amberglen Blvd Ste 100, AUSTIN, TX 78729-1153, United States. The biotechnology company can be reached via phone at +1-512-8961555 or via email at [email protected]


MarketBeat Community Rating for Molecular Templates (MTEM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Molecular Templates (NASDAQ:MTEM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.20$5.20$5.20$5.37
Price Target Upside: 862.96% upside862.96% upside862.96% upside895.06% upside

Molecular Templates (NASDAQ:MTEM) Consensus Price Target History

Price Target History for Molecular Templates (NASDAQ:MTEM)

Molecular Templates (NASDAQ:MTEM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$10.00HighView Rating Details
8/3/2017Stifel NicolausReiterated RatingHold$0.40LowView Rating Details
10/3/2016William BlairReiterated RatingOutperformN/AView Rating Details
9/30/2016S&P Equity ResearchLower Price Target$7.37 -> $5.72N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Molecular Templates (NASDAQ:MTEM) Earnings History and Estimates Chart

Earnings by Quarter for Molecular Templates (NASDAQ:MTEM)

Molecular Templates (NASDAQ MTEM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018        
11/14/2017Q3 2017($0.62)$0.65 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.77)$0.22$3.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.88)($0.77)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.77)($0.55)ViewN/AView Earnings Details
11/7/2016Q3($0.99)($0.88)ViewN/AView Earnings Details
8/1/2016Q216($1.10)($1.10)ViewN/AView Earnings Details
5/5/2016Q1($0.22)($1.21)ViewN/AView Earnings Details
3/10/2016Q4($1.21)$9.46$4.51 million$65.87 millionViewN/AView Earnings Details
11/2/2015Q315($1.54)($0.99)$3.69 million$3.70 millionViewN/AView Earnings Details
7/30/2015Q2($1.54)($1.32)$3.70 million$3.68 millionViewN/AView Earnings Details
4/30/2015($1.54)($1.87)$3.44 million$3.68 millionViewN/AView Earnings Details
3/3/2015Q414($1.43)($1.32)$4.34 million$3.68 millionViewN/AView Earnings Details
11/3/2014Q314($1.32)($1.65)$3.82 million$3.70 millionViewN/AView Earnings Details
8/1/2014($1.43)($1.32)$4.00 million$3.68 millionViewN/AView Earnings Details
5/1/2014($1.10)($1.32)$9.81 million$3.68 millionViewN/AView Earnings Details
3/6/2014Q413($1.10)($1.43)$3.58 million$3.20 millionViewN/AView Earnings Details
11/4/2013Q313($1.54)$0.22$3.15 million$3.20 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.99)($1.32)$3.69 million$3.18 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.99)($1.76)$2.80 million$2.90 millionViewN/AView Earnings Details
3/7/2013Q4 2012($1.32)($5.06)ViewN/AView Earnings Details
11/2/2012Q312($0.66)($0.66)$2.29 million$1.80 millionViewN/AView Earnings Details
8/2/2012Q2 2012($1.10)($0.44)ViewN/AView Earnings Details
5/3/2012Q1 2012$1.65($1.56)ViewN/AView Earnings Details
3/8/2012Q4 2011($1.54)($1.58)ViewN/AView Earnings Details
11/3/2011Q3 2011($1.65)($1.76)ViewN/AView Earnings Details
8/4/2011Q2 2011($1.76)($1.78)ViewN/AView Earnings Details
5/12/2011Q1 2011($1.87)($2.52)ViewN/AView Earnings Details
3/24/2011Q4 2010($2.31)($2.13)ViewN/AView Earnings Details
11/4/2010Q3 2010($2.20)($1.94)ViewN/AView Earnings Details
8/5/2010Q2 2010($1.98)($0.09)ViewN/AView Earnings Details
5/7/2010Q1 2010($1.98)($1.95)ViewN/AView Earnings Details
3/4/2010Q4 2009($1.98)($1.61)ViewN/AView Earnings Details
11/5/2009Q3 2009($4.62)($4.44)ViewN/AView Earnings Details
8/6/2009Q2 2009($3.74)($4.51)ViewN/AView Earnings Details
5/7/2009Q1 2009($3.63)($4.73)ViewN/AView Earnings Details
3/5/2009Q4 2008($3.47)ViewN/AView Earnings Details
11/6/2008Q3 2008($8.58)($5.34)ViewN/AView Earnings Details
8/7/2008Q2 2008($9.24)($7.00)ViewN/AView Earnings Details
5/7/2008Q1 2008($8.84)ViewN/AView Earnings Details
3/6/2008Q4 2007($13.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Molecular Templates (NASDAQ:MTEM) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.32 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS

Dividends

Dividend History for Molecular Templates (NASDAQ:MTEM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Molecular Templates (NASDAQ MTEM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.97%
Institutional Ownership Percentage: 14.70%
Insider Trades by Quarter for Molecular Templates (NASDAQ:MTEM)
Insider Trades by Quarter for Molecular Templates (NASDAQ:MTEM)

Molecular Templates (NASDAQ MTEM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2017Jeffrey W BirdDirectorBuy510,703$0.57$291,100.71919View SEC Filing  
2/18/2015Wilfred E JaegerDirectorBuy25,000$3.75$93,750.00View SEC Filing  
10/13/2014Nipun DavarVPBuy3,000$2.99$8,970.00View SEC Filing  
10/1/2014Hill Ventures SutterMajor ShareholderSell226,657$3.77$854,496.89View SEC Filing  
10/1/2014Jeffrey W BirdDirectorSell238,520$3.77$899,220.40View SEC Filing  
6/20/2014David L AndersonMajor ShareholderSell13,988$4.01$56,091.88View SEC Filing  
1/16/2014Wilfred JaegerDirectorSell96,356$4.86$468,290.16View SEC Filing  
1/15/2014Wilfred JaegerDirectorSell424,956$4.87$2,069,535.72View SEC Filing  
1/10/2014Wilfred JaegerDirectorSell723,900$4.88$3,532,632.00View SEC Filing  
7/15/2013Wilfred E JaegerDirectorSell322,000$5.53$1,780,660.00View SEC Filing  
7/11/2013Wilfred E JaegerDirectorSell178,000$5.51$980,780.00View SEC Filing  
7/5/2013Wilfred E JaegerDirectorSell219,667$5.53$1,214,758.51View SEC Filing  
6/19/2013Wilfred E JaegerDirectorSell2,000$5.50$11,000.00View SEC Filing  
6/18/2013Wilfred E JaegerDirectorSell124,733$5.51$687,278.83View SEC Filing  
6/10/2013Wilfred E JaegerDirectorSell153,600$5.48$841,728.00View SEC Filing  
5/31/2013David L AndersonMajor ShareholderSell266,542$5.72$1,524,620.24View SEC Filing  
5/31/2013Jeffrey W BirdDirectorSell273,181$5.72$1,562,595.32View SEC Filing  
5/22/2013Tillman PearceInsiderSell20,000$5.63$112,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Molecular Templates (NASDAQ MTEM) News Headlines

Source:
DateHeadline
Molecular Templates (MTEM) Upgraded to "Hold" by ValuEngineMolecular Templates (MTEM) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - February 4 at 9:46 PM
Molecular Templates (MTEM) Downgraded by BidaskClub to BuyMolecular Templates (MTEM) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - January 31 at 10:54 PM
Financial Comparison: Threshold Pharmaceuticals (MTEM) & Madrigal Pharmaceuticals (MDGL)Financial Comparison: Threshold Pharmaceuticals (MTEM) & Madrigal Pharmaceuticals (MDGL)
www.americanbankingnews.com - January 15 at 5:38 AM
Molecular Templates Provides Corporate Update and Outlines 2018 MilestonesMolecular Templates Provides Corporate Update and Outlines 2018 Milestones
finance.yahoo.com - January 5 at 9:01 AM
DURECT (DRRX) & Threshold Pharmaceuticals (MTEM) Financial AnalysisDURECT (DRRX) & Threshold Pharmaceuticals (MTEM) Financial Analysis
www.americanbankingnews.com - December 25 at 9:42 AM
Threshold Pharmaceuticals (MTEM) Upgraded to Strong-Buy by BidaskClubThreshold Pharmaceuticals (MTEM) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - December 23 at 1:28 PM
Did Molecular Templates Inc (NASDAQ:MTEM) Create Value For Shareholders?Did Molecular Templates Inc (NASDAQ:MTEM) Create Value For Shareholders?
finance.yahoo.com - December 19 at 5:51 PM
Molecular Templates Inc (MTEM.OQ)Molecular Templates Inc (MTEM.OQ)
www.reuters.com - December 8 at 5:43 PM
GALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of StaffGALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff
www.rttnews.com - December 5 at 9:16 AM
ValuEngine Lowers Threshold Pharmaceuticals (MTEM) to SellValuEngine Lowers Threshold Pharmaceuticals (MTEM) to Sell
www.americanbankingnews.com - December 3 at 6:30 AM
Tesla Is the Exception That Proves the Rule on Board PayTesla Is the Exception That Proves the Rule on Board Pay
www.bloomberg.com - November 30 at 9:03 AM
Zacks Investment Research Lowers Threshold Pharmaceuticals, Inc. (MTEM) to SellZacks Investment Research Lowers Threshold Pharmaceuticals, Inc. (MTEM) to Sell
www.americanbankingnews.com - November 23 at 9:16 PM
Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare ConferenceMolecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 5:43 AM
Global Pancreatic Cancer Market share will Increase US$ 13 Billion By 2021Global Pancreatic Cancer Market share will Increase US$ 13 Billion By 2021
www.marketwatch.com - November 15 at 6:33 AM
Molecular Templates, Inc. Reports Third Quarter 2017 Financial ResultsMolecular Templates, Inc. Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 6:33 AM
Critical Contrast: Threshold Pharmaceuticals (MTEM) versus The CompetitionCritical Contrast: Threshold Pharmaceuticals (MTEM) versus The Competition
www.americanbankingnews.com - October 25 at 7:10 PM
Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)
finance.yahoo.com - October 25 at 7:48 AM
Analyzing Threshold Pharmaceuticals (MTEM) & Cempra (CEMP)Analyzing Threshold Pharmaceuticals (MTEM) & Cempra (CEMP)
www.americanbankingnews.com - October 8 at 6:16 PM
Molecular Templates to Present at the 2017 BIO Investor ForumMolecular Templates to Present at the 2017 BIO Investor Forum
finance.yahoo.com - October 6 at 9:32 AM
Analyzing Threshold Pharmaceuticals (MTEM) & Its PeersAnalyzing Threshold Pharmaceuticals (MTEM) & Its Peers
www.americanbankingnews.com - October 3 at 8:26 AM
Heres Why Spectrum Pharmaceuticals, Inc. Is Surging TodayHere's Why Spectrum Pharmaceuticals, Inc. Is Surging Today
www.fool.com - September 28 at 6:59 PM
Molecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry ConferenceMolecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference
finance.yahoo.com - September 7 at 6:26 AM
Molecular Templates to Ring NASDAQ Closing Bell Friday, September 1, 2017Molecular Templates to Ring NASDAQ Closing Bell Friday, September 1, 2017
finance.yahoo.com - August 31 at 7:30 AM
Head to Head Survey: Corvus Pharmaceuticals (CRVS) vs. Threshold Pharmaceuticals (MTEM)Head to Head Survey: Corvus Pharmaceuticals (CRVS) vs. Threshold Pharmaceuticals (MTEM)
www.americanbankingnews.com - August 23 at 4:26 AM
Austin biotech company lands on Nasdaq with fresh $60 millionAustin biotech company lands on Nasdaq with fresh $60 million
www.bizjournals.com - August 17 at 5:27 AM
 Brokerages Anticipate Threshold Pharmaceuticals, Inc. (MTEM) Will Announce Earnings of -$0.33 Per Share Brokerages Anticipate Threshold Pharmaceuticals, Inc. (MTEM) Will Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - August 16 at 2:14 PM
Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare ConferenceMolecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 15 at 2:22 AM
Molecular Templates Potential Catalysts, Merger Synergies and Pipeline ReviewMolecular Templates Potential Catalysts, Merger Synergies and Pipeline Review
finance.yahoo.com - August 11 at 6:42 AM
Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next-Generation Oncology TherapiesTakeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next-Generation Oncology Therapies
www.businesswire.com - August 4 at 5:48 AM
Molecular Templates Completes Merger with Threshold Pharmaceuticals and Private PlacementsMolecular Templates Completes Merger with Threshold Pharmaceuticals and Private Placements
globenewswire.com - August 4 at 5:48 AM
Benzingas Top Upgrades, Downgrades For August 3, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For August 3, 2017 - Benzinga
www.benzinga.com - August 3 at 12:52 PM
Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next ... - Business Wire (press release)Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next ... - Business Wire (press release)
www.businesswire.com - August 3 at 12:52 PM
5.87 - MarketWatch5.87 - MarketWatch
www.marketwatch.com - August 3 at 12:52 PM

SEC Filings

Molecular Templates (NASDAQ:MTEM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Molecular Templates (NASDAQ:MTEM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Molecular Templates (NASDAQ MTEM) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.